Chronic Pain
Conditions
Keywords
Chronic Pain, AZD2066
Brief summary
The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other
Interventions
DRUGAZD2066
12 doses, Given as capsule, 2 mg & 8 mg
DRUGCaffeine
2 doses, Given as Tablet, 2x50 mg
DRUGTolbutamide
2 doses, Given as Tablet, half of 500 mg
DRUGOmeprazole Tablet, 20 mg
2 doses, Given as Tablet, 20 mg
DRUGMidazolam Tablet, 7.5 mg
2 doses, Given as Tablet, 7.5 mg
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Provision of informed consent prior to any study-specific procedures * Healthy volunteers with BMI between 18 and 30 kg/m2 * Medical and surgical history and physical examination without any clinically significant findings * Non smokers or past smokers who have stopped smoking within the last 6 months.
Exclusion criteria
* History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, personality disorder or other significant psychiatric disorders or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator * Clinically significant illness as judged by the Investigator, within four weeks before the first administration of investigational product. * Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK variables | Frequent sampling occasions during |
Secondary
| Measure | Time frame |
|---|---|
| Safety variables (adverse events, blood pressure, pulse, safety lab) | Frequent sampling occasions during |
Countries
United Kingdom
Outcome results
None listed